Anticoagulation Therapy
The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2016
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_66919 | ||
| 005 | 20210420 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210420s2016 xx |||||o ||| 0|eng d | ||
| 020 | |a 61447 | ||
| 020 | |a 9789535126676 | ||
| 020 | |a 9789535126669 | ||
| 020 | |a 9789535173090 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.5772/61447 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MMG |2 bicssc | |
| 100 | 1 | |a Basaran, Ozcan |4 edt | |
| 700 | 1 | |a Biteker, Murat |4 edt | |
| 700 | 1 | |a Basaran, Ozcan |4 oth | |
| 700 | 1 | |a Biteker, Murat |4 oth | |
| 245 | 1 | 0 | |a Anticoagulation Therapy |
| 260 | |b IntechOpen |c 2016 | ||
| 300 | |a 1 electronic resource (150 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a The available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |4 https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a Pharmacology | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mts.intechopen.com/storage/books/5173/authors_book/authors_book.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/66919 |7 0 |z DOAB: description of the publication |